Bayer Us Patient Assistance Foundation

Critical framing: The Bayer US Patient Assistance Foundation is not a traditional grantmaking foundation. It does not issue grants to nonprofit organizations, academic institutions, or community groups. Rather, it is a corporate operating foundation that functions as a pharmaceutical patient assistance program (PAP) — distributing free Bayer prescription medications directly to eligible patients who are uninsured, underinsured, or whose Bayer prescription is not covered by their insurance plan.

The foundation's charitable work flows through two channels: direct patient enrollment and indirect support through healthcare provider facilitation. Patients apply individually; there is no competitive RFP process and no proposal submission. Healthcare organizations — particularly safety-net clinics, federally qualified health centers (FQHCs), hospital social work departments, patient navigators, and community health workers — can engage with this foundation as a resource for their patient populations rather than as a grant recipient.

Who should engage: The primary 'grant seekers' in this context are individual patients with demonstrated financial need who rely on Bayer medications. The secondary constituency is healthcare providers and patient advocacy organizations that navigate financial assistance programs on behalf of patients — these entities should integrate the Bayer US PAF into their standard financial screening protocols.

Organizational strategy: Social service organizations, FQHC networks, and hospital systems should designate a staff member to maintain current knowledge of the Bayer US PAF formulary, eligibility criteria, and application process. Proactively training clinicians on the pre-populated fax application service can significantly reduce processing friction. The foundation's Find Help tool at patientassistance.bayer.us/en/find-help is a useful decision-support resource for patient navigators determining whether a given patient qualifies.

Relationship building: There is no foundation program officer or relationship manager to cultivate in the traditional sense. Patient assistance decisions are made administratively against defined eligibility criteria. Consistency, accurate documentation, and timely application submission are the core competencies that drive successful access.

Volume and scale: The Bayer US Patient Assistance Foundation operates at a scale that dwarfs most traditional health foundations. In FY2024, the foundation received approximately $1.5 billion in contributions from Bayer AG and disbursed $1.37 billion in charitable distributions — nearly all in the form of pharmaceutical product value transferred to qualifying patients. In FY2023 alone, grants paid totaled $915.2 million against $972.5 million in revenue. FY2022 saw $546 million in disbursements. This represents roughly 40-fold growth from FY2013's $38 million baseline.

Nature of 'giving': All giving is in-kind pharmaceutical product distribution — not cash grants. The foundation's 990-PF filings show the single programmatic grantee entity is structured around HIPAA compliance reporting (listed as 'Under The Health Insurance Portability And Account'), with all disbursements flowing to patients in New Jersey (administrative domicile state) and across the United States and Puerto Rico.

Funding source: 100% of revenue derives from Bayer AG contributions. There is zero net investment income and zero earned revenue. The foundation is entirely a conduit for corporate philanthropy converted into pharmaceutical product access.

Asset base: As of FY2024, net assets were approximately $313 million — essentially a working capital float representing one to three months of annual disbursements. Assets grew from $2.7 million in FY2012 to $184 million in FY2023 to $313 million in FY2024, reflecting both scaling and intentional reserve building.

Geographic scope: Although incorporated in New Jersey, the program is national — serving US residents and those in Puerto Rico. There are no state-specific grant allocations; eligibility is uniform nationwide based on federal poverty guidelines.

Program focus: 100% of charitable activity is in the Health — General and Rehabilitative / Health Support Services NTEE category (E60). There is no education, environmental, or general philanthropic giving. All coverage is limited to Bayer-manufactured prescription products.

The Bayer US Patient Assistance Foundation occupies a structurally unique position among health-focused foundations. While its assets (~$313M) are comparable to peer health foundations in the $260M–$376M range, its annual disbursements ($1.37B in FY2024) are an order of magnitude larger because it functions as a high-velocity pharmaceutical pass-through rather than an endowment-driven grantmaker. The comparisons below illustrate this structural distinction:

The most critical distinction is that Bayer US PAF gives entirely in pharmaceutical product value, not cash, and gives to individual patients, not organizations. A health nonprofit seeking operating support or programmatic grants should look to foundations like UniHealth, Nextfifty, or Natrona Collective — entities that fund organizations. The Bayer US PAF is best understood as a benefits navigation resource for the patients those organizations serve.

The most significant operational change in 2025 was the expansion of the financial eligibility threshold to 300% of the Federal Poverty Limit, effective January 1, 2025. This change meaningfully broadens access for patients who earn modestly above poverty-level income but still cannot afford specialty medications — particularly relevant for Bayer's oncology portfolio (NUBEQA for prostate cancer, Vitrakvi for TRK fusion cancer) where list prices can reach $10,000–$20,000 per month.

A concurrent policy change stemming from the Inflation Reduction Act requires Medicare patients below 150% FPL to submit proof of LIS denial before applying. This adds an administrative step but also reflects the IRA's intent to route low-income Medicare patients to expanded subsidy programs first. Patient navigators working with Medicare populations should factor in the 3-6 week timeline to obtain Social Security Administration LIS denial documentation.

On the financial scale front, FY2024 IRS filings (as captured by ProPublica) show revenue reaching $1.5 billion — a 55% increase from FY2023's $972 million and a doubling from FY2022's $568 million. This growth trajectory suggests Bayer AG continues to expand the scope and value of products channeled through the foundation, likely as part of broader access and affordability commitments.

No leadership changes were publicly announced in 2025-2026. President Albert Mitchell and Chair Michael J. McDonald have been consistent in the filings across multiple years. All officer compensation remains at $0, consistent with the foundation's structure as a corporate operating vehicle staffed by Bayer employees.

Understand what you are applying for: This is a direct pharmaceutical assistance program, not a competitive grant. Eligibility is objective — meet the income limit, lack adequate insurance coverage for the specific Bayer medication, and live in the US or Puerto Rico. There is no narrative, no proposal, and no scoring rubric.

Verify medication coverage first: The foundation covers specific Bayer-manufactured prescription products. Before starting the application, confirm the patient's prescribed medication is on the current formulary by calling 1-866-228-7723 (Mon–Fri, 9am–6pm ET) or using the Find Help tool at patientassistance.bayer.us/en/find-help.

Use the pre-populated fax service: Healthcare providers and their office staff can call the foundation's helpline to request a pre-populated application faxed directly to the physician's office. This eliminates transcription errors and accelerates turnaround. Always include a fax cover sheet with the patient's name, date of birth, and requested medication.

Gather income documentation before starting: The foundation requires proof that household income is at or below 300% FPL. Acceptable documentation typically includes recent tax returns, pay stubs, or benefit statements. For Medicare patients below 150% FPL, obtain a Social Security Administration letter confirming LIS denial before submitting — without it, the application will be incomplete.

Complete both sections completely: The enrollment form has two mandatory sections: a Patient Information Section (completed by the patient) and a Healthcare Professional Section (completed by the prescribing physician or other licensed provider). Incomplete applications — particularly missing physician signatures or missing insurance denial documentation — are the most common cause of processing delays.

Set expectations on timeline: Once submitted, decisions are communicated by letter. After approval, a foundation representative contacts the patient by phone to schedule medication shipment. Patients should expect 2-4 weeks from submission to decision under normal processing volumes.

Renewal and ongoing enrollment: This is an enrollment-based program, not a one-time grant. Patients re-enroll annually and must re-certify income eligibility. Build annual renewal reminders into care coordination workflows.